Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 9/20 | 0.75 |
| ▸ | ITGAV | P06756 | 8/20 | 0.75 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.75 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.54 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.54 |
| ▸ | LDLR | P01130 | 10/20 | 0.48 |
| ▸ | PCSK9 | Q8NBP7 | 10/20 | 0.48 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.44 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.43 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eptifibatide SCHEMBL22193879 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGA5 | |
| Eptifibatide SCHEMBL18504808 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGA5 | |
| Eptifibatide SCHEMBL43237 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGA5 | |
| Eptifibatide SCHEMBL16884017 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGA5 | |
| Eptifibatide SCHEMBL1649793 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGA5 | |
| Eptifibatide SCHEMBL29353236 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGA5 | |
| Eptifibatide SCHEMBL16883987 | 0.86 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGA5 | |
| SCHEMBL24433345 | 0.85 | ITGB3 (0.86) | ITGB3ITGAVITGA2BITGB5ITGA5 | |
| SCHEMBL29356871 | 0.84 | ITGB3 (0.97) | ITGB3ITGAVITGA2BITGB5ITGA5 | |
| SCHEMBL18504954 | 0.79 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB5ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153812-A1 | INTEGRIN ANTAGONISTS | THE GENERAL HOSPITAL CORPORATION | 2022-05-19 | — | — | US | disclosed |
| US-20200216517-A1 | Integrin Antagonists | THE GENERAL HOSPITAL CORPORATION | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153812-A1 | INTEGRIN ANTAGONISTS | ITGB3, ITGA2B, ITGB1 | ITGB3 1/4885ITGAV 8/4885ITGA2B 2/4885 |
| US-20200216517-A1 | Integrin Antagonists | ITGB3, ITGA2B, ITGB1 | ITGB3 1/4885ITGAV 8/4885ITGA2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.